The IGF hormonal network in endometrial cancer: functions, regulation and targeting approaches
Epidemiological as well as clinical and experimental data identified the insulin-like growth factors (IGF1, IGF2) as important players in gynecological cancers in general, and endometrial tumors in particular. The IGF1 receptor (IGF1R), which mediates the proliferative and anti-apoptotic activities...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2014-05-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fendo.2014.00076/full |
| _version_ | 1818056660521844736 |
|---|---|
| author | Ilan eBruchim Rive eSarfstein Haim eWerner |
| author_facet | Ilan eBruchim Rive eSarfstein Haim eWerner |
| author_sort | Ilan eBruchim |
| collection | DOAJ |
| description | Epidemiological as well as clinical and experimental data identified the insulin-like growth factors (IGF1, IGF2) as important players in gynecological cancers in general, and endometrial tumors in particular. The IGF1 receptor (IGF1R), which mediates the proliferative and anti-apoptotic activities of both ligands, emerged in recent years as a promising therapeutic target in oncology. However, most clinical trials conducted so far led to mixed results, emphasizing the need to identify biomarkers that can predict responsiveness to anti-IGF1R targeted therapies. This article will review recent data regarding the role and expression of IGF system components in endometrial cancer. In addition, we will review data on the interplay between the IGF signaling pathway and tumor suppressors p53 and BRCA1. Antioncogenes p53 and BRCA1 play a key role in the etiology of gynecological cancers and, therefore, their interaction with IGF1R is of high relevance in translational terms. A better understanding of the complex mechanisms underlying the regulation of the IGF system will improve our ability to develop effective treatment modalities for endometrial tumors. |
| first_indexed | 2024-12-10T12:32:22Z |
| format | Article |
| id | doaj.art-b1097c4365544015877b36704debe809 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-10T12:32:22Z |
| publishDate | 2014-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-b1097c4365544015877b36704debe8092022-12-22T01:48:47ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922014-05-01510.3389/fendo.2014.0007691120The IGF hormonal network in endometrial cancer: functions, regulation and targeting approachesIlan eBruchim0Rive eSarfstein1Haim eWerner2Gynecologic Oncology UnitSackler School of Medicine, Tel Aviv UniversitySackler School of Medicine, Tel Aviv UniversityEpidemiological as well as clinical and experimental data identified the insulin-like growth factors (IGF1, IGF2) as important players in gynecological cancers in general, and endometrial tumors in particular. The IGF1 receptor (IGF1R), which mediates the proliferative and anti-apoptotic activities of both ligands, emerged in recent years as a promising therapeutic target in oncology. However, most clinical trials conducted so far led to mixed results, emphasizing the need to identify biomarkers that can predict responsiveness to anti-IGF1R targeted therapies. This article will review recent data regarding the role and expression of IGF system components in endometrial cancer. In addition, we will review data on the interplay between the IGF signaling pathway and tumor suppressors p53 and BRCA1. Antioncogenes p53 and BRCA1 play a key role in the etiology of gynecological cancers and, therefore, their interaction with IGF1R is of high relevance in translational terms. A better understanding of the complex mechanisms underlying the regulation of the IGF system will improve our ability to develop effective treatment modalities for endometrial tumors.http://journal.frontiersin.org/Journal/10.3389/fendo.2014.00076/fullBiomarkers, PharmacologicalIGF1BRCA1endometrial cancerinsulin-like growth factorsp53 |
| spellingShingle | Ilan eBruchim Rive eSarfstein Haim eWerner The IGF hormonal network in endometrial cancer: functions, regulation and targeting approaches Frontiers in Endocrinology Biomarkers, Pharmacological IGF1 BRCA1 endometrial cancer insulin-like growth factors p53 |
| title | The IGF hormonal network in endometrial cancer: functions, regulation and targeting approaches |
| title_full | The IGF hormonal network in endometrial cancer: functions, regulation and targeting approaches |
| title_fullStr | The IGF hormonal network in endometrial cancer: functions, regulation and targeting approaches |
| title_full_unstemmed | The IGF hormonal network in endometrial cancer: functions, regulation and targeting approaches |
| title_short | The IGF hormonal network in endometrial cancer: functions, regulation and targeting approaches |
| title_sort | igf hormonal network in endometrial cancer functions regulation and targeting approaches |
| topic | Biomarkers, Pharmacological IGF1 BRCA1 endometrial cancer insulin-like growth factors p53 |
| url | http://journal.frontiersin.org/Journal/10.3389/fendo.2014.00076/full |
| work_keys_str_mv | AT ilanebruchim theigfhormonalnetworkinendometrialcancerfunctionsregulationandtargetingapproaches AT riveesarfstein theigfhormonalnetworkinendometrialcancerfunctionsregulationandtargetingapproaches AT haimewerner theigfhormonalnetworkinendometrialcancerfunctionsregulationandtargetingapproaches AT ilanebruchim igfhormonalnetworkinendometrialcancerfunctionsregulationandtargetingapproaches AT riveesarfstein igfhormonalnetworkinendometrialcancerfunctionsregulationandtargetingapproaches AT haimewerner igfhormonalnetworkinendometrialcancerfunctionsregulationandtargetingapproaches |